Atea Pharmaceuticals Inc
NASDAQ:AVIR
Atea Pharmaceuticals Inc
Other Items
Atea Pharmaceuticals Inc
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Atea Pharmaceuticals Inc
NASDAQ:AVIR
|
Other Items
$188.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Other Items
-$18.8B
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-16%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Other Items
-$2.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
23%
|
CAGR 10-Years
-14%
|
|
|
Pfizer Inc
NYSE:PFE
|
Other Items
$1.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merck & Co Inc
NYSE:MRK
|
Other Items
-$9.6B
|
CAGR 3-Years
-156%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-11%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Other Items
-$123m
|
CAGR 3-Years
46%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
Atea Pharmaceuticals Inc
Glance View
Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 59 full-time employees. The company went IPO on 2020-10-30. The firm is focused on discovering, developing, and commercializing antiviral therapeutics to enhance the lives of patients suffering from life-threatening viral infections. The firm is engaged in the development of product candidates to treat COVID-19, hepatitis C virus (HCV), dengue and respiratory syncytial virus (RSV). The firm is developing bemnifosbuvir (AT-527), which is an investigational, novel, orally administered guanosine nucleotide analog polymerase inhibitor for the treatment of COVID-19. The company is developing bemnifosbuvir and ruzasvir, an investigational nonstructural protein 5A (NS5A) inhibitor for the treatment of chronic HCV infection. The firm is also developing AT-752, an oral, purine nucleotide prodrug for the treatment of dengue. AT-527 is designed to inhibit viral replication by interfering with viral RNA polymerase.
See Also
What is Atea Pharmaceuticals Inc's Other Items?
Other Items
188.8m
USD
Based on the financial report for Dec 31, 2025, Atea Pharmaceuticals Inc's Other Items amounts to 188.8m USD.
What is Atea Pharmaceuticals Inc's Other Items growth rate?
Other Items CAGR 1Y
236%
Over the last year, the Other Items growth was 236%.
